About this trial
This is a cross-sectional, multicenter tissue study with an exploratory aim to estimate the prevalence of genetic mutations that predispose individuals to diseases in the context of cholestatic disorders and hepatobiliary neoplasms. It is intended as a hypothesis-generating study for future empirical investigations.
Eligibility criteria
Qualifiers
Instrumental or histological diagnosis of HBCs, defined as primary liver and/or biliary tumors (hepatocellular carcinoma, cholangiocarcinoma, hepatocholangiocarcinoma) occurring in patients without apparent underlying chronic liver disease or in the context of cryptogenic chronic liver disease;
Curative treatment through surgical resection of the neoplasm or liver transplantation
GGT and/or alkaline phosphatase >1.5 times the normal values in two or more measurements taken at least 6 months apart,
A history of pruritus combined with [BA] >10 mmol/l for a period of ≥6 months.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed